Announcement of TTY Biopharm's unaudited income information in June 2025
2025.7.10
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2025/07/10 | Time of announcement | 15:53:27 |
| Subject | Announcement of TTY Biopharm's unaudited income information in June 2025 | ||||
| Date of events | 2025/07/10 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2025/07/10 2.Company name:TTY Biopharm Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $535,291 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $152,115 thousands, and a consolidated income before tax of $175,608 thousands in June 2025; net income attributed to stockholders of the company was $133,973 thousands; EPS is $0.54. Year-to-date consolidated net sales was $2,971,263 thousands (in NTdollars; unaudited), a consolidated operating profit was $818,634 thousands, and consolidated income before tax was $909,227 thousands until June 2025; year-to-date net income attributed to stockholders of the company was $677,928 thousands; EPS is $2.73. 6.Countermeasures:None. 7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail. |
||||